Helsinn Therapeutics (U.S.), Inc. waives copay fees for cancer-treating drug VALCHLOR® (mechlorethamine) gel to ensure eligible patients have access to treatment during the COVID-19 crisis

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement